Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Pharmacology of ADP-ribosylation

Schüler, Herwig LU orcid and Ziegler, Mathias (2013) In The FEBS Journal 280(15). p.3542-3542
Abstract

ADP-ribosyltransferase ARTD1/PARP1 is a target for cancer and ischemia drug development. Several other ARTD-family enzymes have been characterized in recent years, and it has become clear that their inhibition might also have therapeutic value. This minireview series summarizes current knowledge of pharmacological inhibition of ADP-ribosyltransferases by a compound class called PARP inhibitors and the prospects for drug development.

Please use this url to cite or link to this publication:
author
and
publishing date
type
Contribution to journal
publication status
published
keywords
Adenosine Diphosphate Ribose/metabolism, Humans, Ischemia/drug therapy, Molecular Targeted Therapy, Neoplasms/drug therapy, Poly(ADP-ribose) Polymerase Inhibitors, Poly(ADP-ribose) Polymerases/metabolism, Protein Processing, Post-Translational/drug effects
in
The FEBS Journal
volume
280
issue
15
pages
3542 - 3542
publisher
John Wiley & Sons Inc.
external identifiers
  • scopus:84880333750
  • pmid:23763848
ISSN
1742-464X
DOI
10.1111/febs.12388
language
English
LU publication?
no
additional info
© 2013 FEBS.
id
55dff679-a960-48db-b455-19f752818f03
date added to LUP
2024-11-21 17:56:09
date last changed
2025-03-14 13:08:56
@article{55dff679-a960-48db-b455-19f752818f03,
  abstract     = {{<p>ADP-ribosyltransferase ARTD1/PARP1 is a target for cancer and ischemia drug development. Several other ARTD-family enzymes have been characterized in recent years, and it has become clear that their inhibition might also have therapeutic value. This minireview series summarizes current knowledge of pharmacological inhibition of ADP-ribosyltransferases by a compound class called PARP inhibitors and the prospects for drug development.</p>}},
  author       = {{Schüler, Herwig and Ziegler, Mathias}},
  issn         = {{1742-464X}},
  keywords     = {{Adenosine Diphosphate Ribose/metabolism; Humans; Ischemia/drug therapy; Molecular Targeted Therapy; Neoplasms/drug therapy; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases/metabolism; Protein Processing, Post-Translational/drug effects}},
  language     = {{eng}},
  number       = {{15}},
  pages        = {{3542--3542}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{The FEBS Journal}},
  title        = {{Pharmacology of ADP-ribosylation}},
  url          = {{http://dx.doi.org/10.1111/febs.12388}},
  doi          = {{10.1111/febs.12388}},
  volume       = {{280}},
  year         = {{2013}},
}